Get Molecular Testing - Canada
(non-ON/non-QC)
As of July 1st, 2024, patients living with cholangiocarcinoma that reside outside of Ontario and Quebec will be able to access molecular testing from OncoHelix Labs, in partnership with the C3. OncoHelix-C3 molecular testing will use the 170 gene CGP "OncoHelix-2" panel, which can detect FGFR2 fusions and other DNA/RNA biomarkers (see below for full list).
Patients and treating physicians will receive a complete clinical report of Tier I (variants of strong clinical significance) and Tier II (variants of potential clinical significance) alterations in DNA and RNA biomarkers.
Important information:
-
Patients must be a "C3 Patient Member"
-
Please ask your patients to fill out the
C3 Patient Intake form
-
-
The OncoHelix-C3​ test requisition form should be submitted to c3@ohri.ca
-
Sample and Pathology details are on Page 2
-
-
Biopsy brushings are accepted and will undergo OncoHelix's standard Quality Control tests to ensure suitability for molecular testing.
-
If you are submitting brushings, please check "Other" and specify.
-
Links for OncoHelix x C3:
NOTICE FOR ALBERTA ONLY:
For molecular testing requests from Alberta, please contact the c3@ohri.ca first before submitting a test requisition form.
Contact and Assistance Information:
*OncoHelix Labs is accredited by the College of Physicians and Surgeons of Alberta (CPSA) and performs all testing to CPSA Standards
